serw-MX  [xml]  
 


    
 DeCS Categories

C10 Nervous System Diseases .
C10.228 Central Nervous System Diseases .
C10.228.662 Movement Disorders .
D02 Organic Chemicals .
D02.241 Carboxylic Acids .
D02.241.081 Acids, Acyclic .
D02.241.081.018 Acetates .
D02.241.081.018.386 Glycolates .
D02.241.081.018.386.682 Phenoxyacetates .
D02.241.081.018.386.682.300 Ethacrynic Acid .
D02.241.511 Hydroxy Acids .
D02.241.511.316 Glycolates .
D02.241.511.316.682 Phenoxyacetates .
D02.241.511.316.682.200 Ethacrynic Acid .
D02.455 Hydrocarbons .
D02.455.426 Hydrocarbons, Cyclic .
D02.455.426.559 Hydrocarbons, Aromatic .
D02.455.426.559.389 Benzene Derivatives .
D02.455.426.559.389.097 Benzenesulfonates .
D02.455.426.559.389.097.250 Ethamsylate .
D02.640 Nitro Compounds .
D02.640.672 Nitroimidazoles .
D02.640.672.250 Etanidazole .
D02.886 Sulfur Compounds .
D02.886.645 Sulfur Acids .
D02.886.645.600 Sulfonic Acids .
D02.886.645.600.080 Arylsulfonic Acids .
D02.886.645.600.080.050 Arylsulfonates .
D02.886.645.600.080.050.100 Benzenesulfonates .
D02.886.645.600.080.050.100.300 Ethamsylate .
D03 Heterocyclic Compounds .
D03.066 Acids, Heterocyclic .
D03.066.515 Nicotinic Acids .
D03.066.515.400 Etazolate .
D03.383 Heterocyclic Compounds, 1-Ring .
D03.383.129 Azoles .
D03.383.129.308 Imidazoles .
D03.383.129.308.658 Nitroimidazoles .
D03.383.129.308.658.250 Etanidazole .
D03.383.725 Pyridines .
D03.383.725.547 Nicotinic Acids .
D03.383.725.547.400 Etazolate .
D03.383.742 Pyrimidines .
D03.383.742.698 Pyrimidinones .
D03.383.742.698.253 Barbiturates .
D03.383.742.698.253.593 Pentobarbital .
D09 Carbohydrates .
D09.698 Polysaccharides .
D09.698.373 Glycosaminoglycans .
D09.698.373.475 Hyaluronic Acid .
D12 Amino Acids, Peptides, and Proteins .
D12.776 Proteins .
D12.776.124 Blood Proteins .
D12.776.124.486 Immunoproteins .
D12.776.124.486.485 Immunoglobulins .
D12.776.124.486.485.114 Antibodies .
D12.776.124.486.485.114.619 Immunoglobulin Isotypes .
D12.776.124.486.485.114.619.393 Immunoglobulin G .
D12.776.124.486.485.114.619.393.261 Etanercept .
D12.776.124.790 Serum Globulins .
D12.776.124.790.651 Immunoglobulins .
D12.776.124.790.651.114 Antibodies .
D12.776.124.790.651.114.619 Immunoglobulin Isotypes .
D12.776.124.790.651.114.619.393 Immunoglobulin G .
D12.776.124.790.651.114.619.393.261 Etanercept .
D12.776.377 Globulins .
D12.776.377.715 Serum Globulins .
D12.776.377.715.548 Immunoglobulins .
D12.776.377.715.548.114 Antibodies .
D12.776.377.715.548.114.619 Immunoglobulin Isotypes .
D12.776.377.715.548.114.619.393 Immunoglobulin G .
D12.776.377.715.548.114.619.393.261 Etanercept .
D12.776.543 Membrane Proteins .
D12.776.543.750 Receptors, Cell Surface .
D12.776.543.750.705 Receptors, Immunologic .
D12.776.543.750.705.852 Receptors, Cytokine .
D12.776.543.750.705.852.760 Receptors, Tumor Necrosis Factor .
D12.776.543.750.705.852.760.232 Etanercept .
N04 Health Services Administration .
N04.452 Organization and Administration .
N04.452.871 Risk Management .
N04.452.871.758 Risk Evaluation and Mitigation .
N06 Environment and Public Health .
N06.850 Public Health .
N06.850.505 Epidemiologic Measurements .
N06.850.505.715 Risk Assessment .
N06.850.505.715.750 Risk Evaluation and Mitigation .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Pentobarbital .
Diabutal .
Etaminal .
Ethaminal .
Nembutal .
Pentobarbital Sodium .
Pentobarbital, Monosodium Salt .
Pentobarbitone .
Sagatal .
Monosodium Salt Pentobarbital .
Mebubarbital .
Mebumal .
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236) .
1.00
779050
 
Risk Evaluation and Mitigation .
ETASU .
Elements to Assure Safe Use .
Strategies required by the US Food and Drug Administration (FDA) Amendments Act of 2007 when a question exists as to whether the benefits of a drug outweigh its risks. These constitute a safety plan with several potential components, including a medication guide, a communication plan, elements to ensure safe use and an implementation system to help guide the prescribers, pharmacists and patients. .
0.68
20
 
Hyaluronic Acid .
Amo Vitrax .
Amvisc .
Biolon .
Etamucine .
Healon .
Hyaluronan .
Hyaluronate Sodium .
Hyvisc .
Luronit .
Sodium Hyaluronate .
Acid, Hyaluronic .
Hyaluronate, Sodium .
Vitrax, Amo .
A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA. .
0.65
16317806
 
Ethamsylate .
Altodor .
Dicinone .
Dicynene .
Dicynone .
Etamsylate .
Hemo 141 .
Cyclonamine .
Benzenesulfonate derivative used as a systemic hemostatic. .
0.61
1179
 
Etanercept .
Enbrel .
Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein .
TNF Receptor Type II-IgG Fusion Protein .
TNFR-Fc Fusion Protein .
TNR 001 .
TNR-001 .
TNT Receptor Fusion Protein .
TNTR-Fc .
001, TNR .
Fusion Protein, TNFR-Fc .
Protein, TNFR-Fc Fusion .
Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein .
TNF Receptor Type II IgG Fusion Protein .
TNFR Fc Fusion Protein .
TNR001 .
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS. .
0.57
 
Etazolate .
Etazolate Hydrochloride .
SQ-20009 .
Hydrochloride, Etazolate .
SQ 20009 .
SQ20009 .
A potent phosphodiesterase inhibitor proposed as an antipsychotic agent. .
0.56
069
 
Etanidazole .
NSC-301467 .
SR-2508 .
NSC 301467 .
NSC301467 .
SR 2508 .
SR2508 .
A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy. .
0.51
1296
 
Movement Disorders .
Movement Disorder Syndromes .
Dyskinesia Syndrome .
Movement Disorder .
Movement Disorder Syndrome .
Etat Marbre .
Status Marmoratus .
Dyskinesia Syndromes .
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. .
0.49
16413597
 
Ethacrynic Acid .
Edecrin .
Etacrynic Acid .
Ethacrinic Acid .
Ethacrynate Sodium .
Ethacrynic Acid, Sodium Salt .
Hydromedin .
Acid, Etacrynic .
Acid, Ethacrinic .
Acid, Ethacrynic .
Sodium, Ethacrynate .
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. .
0.46
22138